![arrow](/web/20061210202948im_/http://www.hc-sc.gc.ca/dhp-mps/medeff/images/arrow_bullet.gif) |
Important Safety Information on anti-TNFα Therapy: ENBREL (etanercept), HUMIRA (adalimumab), and REMICADE (infliximab)
- For Health Professionals
- For the Public
- Amgen Canada, Inc., Abbott Laboratories, Ltd., and Schering Canada, Inc.
Date: 2006-01-18
|